Compare Sanofi SA (SNY) vs Tapestry, Inc. (TPR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Tapestry, Inc. — how do they compare? Sanofi SA trades at $44.05 (market cap $104.83B), while Tapestry, Inc. trades at $140.62 (market cap $28.51B). The key difference: Sanofi SA is far larger — about 3.7× Tapestry, Inc.'s market cap, and Sanofi SA pays the higher dividend (5.5%). Which is the better fit depends on your goals.
| SNY | TPR | |
|---|---|---|
Market Cap | $104.83B | $28.51B |
Sector | Health | Consumer Cyclical |
52-Week High | $52.34 | $160.49 |
52-Week Low | $41.33 | $95.69 |
Enterprise Value | $121.32B | $31.37B |
Dividend Yield | 5.5% | 1.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNY trades at $43.76, down 2.02% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 results pending. Revenue grew to $46.72B in 2025, with net income margin improving to 16.72%. Recent positive developments include FDA approval for Sarclisa's wearable injector and EU approval for Cenrifki in multiple sclerosis.
Outlook remains positive with analyst consensus leaning toward buy/hold, though regulatory scrutiny in the EU presents near-term risk. The stock offers a solid dividend yield with the upcoming $2.42 payment. Valuation metrics like P/E of 19.5 and P/B of 1.27 suggest reasonable pricing relative to peers, supported by robust cash flow from operations of $10.75B.
TPR trades at $142.16, up 0.49% today, with a neutral technical signal but strong fundamental momentum after three consecutive quarterly earnings beats. The stock carries high valuation ratios, including a P/E of 43.02, but demonstrates robust profitability with a 76.18% gross margin and 55.74% ROE. Recent corporate news includes the appointment of Jonathan Saunders as Kate Spade's Executive Creative Director, signaling brand revitalization efforts.
Outlook remains positive with a consensus price target of $183.88, implying 29% upside, supported by 75.6% analyst buy ratings. Key risks include elevated debt levels and margin compression from 2024's 12.23% to 2025's 2.61% net income margin. Investors should weigh strong brand positioning against valuation sensitivity and cyclical retail exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Tapestry, Inc.
Coach, Kate Spade, and Stuart Weitzman are the fashion and accessory brands that comprise Tapestry. The firm's products are sold through about 1,400 company-operated stores, wholesale channels, and e-commerce in North America (67% of fiscal 2022 sales), Europe, Asia (28% of fiscal 2022 sales), and elsewhere. Coach (74% of fiscal 2022 sales) is best known for affordable luxury leather products. Kate Spade (22% of fiscal 2022 sales) is known for colorful patterns and graphics. Women's handbags and accessories produced 69% of Tapestry's sales in fiscal 2022. Stuart Weitzman, Tapestry's smallest brand, generates nearly all its revenue from women's footwear.
Read more on TPR →
